Amarin | AMRN - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -6.66B 3.39B 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amarin USD 449.41M 9.87M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
BioCryst Pharmaceuticals USD -553.84M 434.69M 2026-03
DBV Technologies USD 168.77M 115.92M 2025-12
Esperion Therapeutics USD -307.93M 5.97M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Halozyme Therapeutics USD 219.64M 170.82M 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03